Scholarlink

Current clinical diagnostic criteria for the diagnosis of Alzheimer disease (AD) include imaging biomarkers as complementary tools that increase the etiological probability of AD. Molecular imaging biomarkers provide additional information on amyloid and tau burden and neurodegeneration that are very helpful in supporting the etiological and differential diagnosis of neurodegenerative diseases associated with dementia, especially in atypical clinical presentations and in the presence of comorbidities. In addition, with the recent availability of disease-modifying therapies, molecular imaging biomarkers are beneficial for patient eligibility and response monitoring to amyloid therapy.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Case 2: Alzheimer’s Disease: [18F]FDG, Tau, and Amyloid PET

  • 章节

  • 发表日期：

    2025年

查看全文
  • Fernando Minguez,
  • Marta Romera,
  • Juan Fernando Bastidas,
  • Mario Riverol,
  • Javier Arbizu

摘要

Current clinical diagnostic criteria for the diagnosis of Alzheimer disease (AD) include imaging biomarkers as complementary tools that increase the etiological probability of AD. Molecular imaging biomarkers provide additional information on amyloid and tau burden and neurodegeneration that are very helpful in supporting the etiological and differential diagnosis of neurodegenerative diseases associated with dementia, especially in atypical clinical presentations and in the presence of comorbidities. In addition, with the recent availability of disease-modifying therapies, molecular imaging biomarkers are beneficial for patient eligibility and response monitoring to amyloid therapy.